Rapport Therapeutics Bolsa (NASDAQ: RAPP)

Rapport Therapeutics

RAPPORT THERAPEUTICS INC

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Sportsman'sSaratoga,Springs,,Utah,,Usa,-,Nov,30,,2024:,Sportsman's,Warehouse

AEHL

AGMH

BIAF

DGLY

GRFS

NCNO

NMAX

QUAD

RAPP

RSLS

SAMG

SBFM

SPWH

STSS

SYRA

Sportsman&#39;s Warehouse sorprende con ingresos y ganancias inesperadas: conoce las cifras que hicieron subir sus acciones.

Acciones de Sportsman&#39;s Warehouse (SPWH) se disparan un 39%; Aquí están 20 acciones moviéndose en premercado

GameStop Corp.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHIL

BSGM

CISO

CLEU

GDHG

HUMA

IMTE

NYXH

ORKA

PTPI

SURG

THTX

TXMD

WINT

ZYBT

El premercado de hoy revela fuertes movimientos bursátiles tras informes financieros y aprobaciones clave en sectores críticos.

Las acciones de GameStop (GME) suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

Press Releases

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

Earnings

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

Health Care

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Rapport Announces Proposed Public Offering of Common Stock

IPOs

Rapport Announces Pricing of Public Offering of Common Stock

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

ANRO

CERE

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ATAI Life Sciences

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Cronos Group

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Hldgs

Harrow

Innoviva

LENZ Therapeutics

Maze Therapeutics

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Nektar Therapeutics

Nuvation Bio

Oculis Holding

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Pharvaris

Septerna

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Truist Securities

HC Wainwright & Co.

JMP Securities

Jones Trading

Stifel

Comments

Rapport Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL